A phase II, 20-week, multi-centre, randomised, double-blind, placebo-controlled, parallel group proof of concept study to investigate the efficacy and safety of GSK1605786 for treatment of patients with active Ulcerative Colitis.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2014
At a glance
- Drugs Vercirnon (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 20 Jun 2013 Status changed from not yet recruiting to withdrawn prior to recruitment.
- 14 Dec 2012 Planned initiation date changed from 1 Jan 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.